Alzheimers & Dementia

Papers
(The H4-Index of Alzheimers & Dementia is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
2021 Alzheimer's disease facts and figures1699
2022 Alzheimer's disease facts and figures1346
2023 Alzheimer's disease facts and figures1153
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)503
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019342
Global estimates on the number of persons across the Alzheimer's disease continuum263
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease235
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease198
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study189
COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US181
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis181
The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning149
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research141
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis128
Alzheimer's‐like signaling in brains of COVID‐19 patients120
Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis119
Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL‐1β drives amplified responses in primed astrocytes and neuronal network dysfunction116
Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta‐analysis112
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities112
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease111
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) wor109
The worldwide costs of dementia in 2019104
World Alzheimer Report 2019: Attitudes to dementia, a global survey102
The impact of diabetes on cognitive impairment and its progression to dementia99
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia99
The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 201997
Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank95
Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study93
Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance91
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis89
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau88
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel88
An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum85
Diagnostic criteria for apathy in neurocognitive disorders85
White matter hyperintensity topography in Alzheimer's disease and links to cognition85
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐J83
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort79
Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics78
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays77
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging76
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance75
Integrative metabolomics‐genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease75
Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation75
Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study74
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis73
Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients72
Dementia in Latin America: Paving the way toward a regional action plan72
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease71
Toward a theory‐based specification of non‐pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations69
2024 Alzheimer's disease facts and figures66
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease64
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau62
ENGAGE and EMERGE: Truth and consequences?62
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease60
Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates58
Whole‐genome sequencing reveals new Alzheimer's disease–associated rare variants in loci related to synaptic function and neuronal development57
Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease57
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective57
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria57
Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial57
0.040373086929321